Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Actinium Pharmaceuticals	Mereo BioPharma Group	Cocrystal Pharma	PhaseBio Pharmaceuticals	Chembio Diagnostics
Symbol	NYSEAMERICAN:ATNM	NASDAQ:MREO	NASDAQ:COCP	NASDAQ:PHAS	NASDAQ:CEMI
Price Information
Current Price	$7.38	$3.29	$1.19	$3.05	$3.82
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.5	1.4	1.4	1.5	1.3
Analysis Score	3.5	3.5	3.5	3.5	3.2
Community Score	3.2	2.2	2.9	2.3	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.8	0.0	0.8	0.0
Earnings & Valuation Score	0.6	0.6	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$41.00	$10.00	$4.75	$12.33	$7.25
% Upside from Price Target	455.56% upside	203.95% upside	299.16% upside	304.37% upside	89.79% upside
Trade Information
Market Cap	$137.42 million	$223.03 million	$80.76 million	$90.10 million	$73.26 million
Beta	1.23	1.69	1.46	1.85	2.05
Average Volume	389,070	2,343,969	2,544,247	581,898	4,761,763
Sales & Book Value
Annual Revenue	N/A	N/A	$6.56 million	$2.36 million	$34.46 million
Price / Sales	N/A	N/A	12.96	38.05	2.24
Cashflow	N/A	N/A	$0.99 per share	N/A	N/A
Price / Cash	N/A	N/A	1.20	N/A	N/A
Book Value	$1.03 per share	$2.06 per share	$0.73 per share	$2.09 per share	$1.37 per share
Price / Book	N/A	N/A	1.63	1.46	2.79
Profitability
Net Income	$-21,900,000.00	$-44,490,000.00	$-48,170,000.00	$-39,250,000.00	$-13,680,000.00
EPS	N/A	($2.49)	($0.06)	($1.43)	($0.79)
Trailing P/E Ratio	0.00	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-2,938.09%	N/A	-76.55%
Return on Equity (ROE)	-77.96%	N/A	-25.81%	-220.57%	-73.70%
Return on Assets (ROA)	-64.62%	N/A	-23.98%	-110.30%	-33.21%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.60%	N/A	1.87%	0.54%
Current Ratio	10.51%	2.99%	12.59%	4.39%	4.07%
Quick Ratio	10.51%	N/A	12.59%	4.39%	2.97%
Ownership Information
Institutional Ownership Percentage	17.55%	62.14%	18.71%	58.58%	31.06%
Insider Ownership Percentage	1.50%	N/A	10.80%	17.00%	3.00%
Miscellaneous
Employees	30	38	13	50	324
Shares Outstanding	19.25 million	67.79 million	71.47 million	29.44 million	20.18 million
Next Earnings Date	N/A	6/30/2021 (Estimated)	5/13/2021 (Estimated)	5/11/2021 (Estimated)	5/3/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Chembio Diagnostics, Inc. (NASDAQ:CEMI) Given Average Rating of "Hold" by Analysts americanbankingnews.com - April 17 at 3:32 AM
	Chembio Diagnostics Stock Is Believed To Be Modestly Undervalued ca.finance.yahoo.com - April 15 at 2:34 PM
	Analysts Expect Chembio Diagnostics, Inc. (NASDAQ:CEMI) to Announce -$0.30 Earnings Per Share americanbankingnews.com - April 13 at 12:22 AM
	If You Had Bought Chembio Diagnostics' (NASDAQ:CEMI) Shares Three Years Ago You Would Be Down 39% finance.yahoo.com - April 7 at 8:35 AM
	CEMI Stock News: Chembio Diagnostics Inc skyrockets 60% after FDA greenlights rapid covid/flu tests fxstreet.com - April 6 at 9:05 AM
	Chembio Jumps on Launch of Test Distinguishing COVID, Flu finance.yahoo.com - April 5 at 6:38 PM
	Chembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 test finance.yahoo.com - April 5 at 6:38 PM
	Traders Buy High Volume of Chembio Diagnostics Call Options (NASDAQ:CEMI) americanbankingnews.com - April 5 at 12:22 PM
	CEMI Stock: Investors Cheer Commercial Launch cnafinance.com - April 5 at 8:37 AM
	Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu finance.yahoo.com - April 1 at 7:12 PM
	Is this the best time to Buy Chembio Diagnostics, Inc. (NASDAQ:CEMI) stock? stocksregister.com - March 27 at 10:48 AM
	Earnings Update: Here's Why Analysts Just Lifted Their Chembio Diagnostics, Inc. (NASDAQ:CEMI) Price Target To US$9.00 nasdaq.com - March 13 at 9:26 AM
	Chembio Diagnostics's Earnings Outlook benzinga.com - March 10 at 12:53 PM
	Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors finance.yahoo.com - March 8 at 8:42 AM
	Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021 finance.yahoo.com - February 25 at 4:51 PM
	Looking for a Top Momentum Stock? Check Out Chembio Diagnostics, Inc. (NASDAQ:CEMI) stocksregister.com - February 8 at 7:26 PM
	Do Insiders Own Lots Of Shares In Chembio Diagnostics, Inc. (NASDAQ:CEMI)? finance.yahoo.com - February 3 at 7:11 AM
	CEMI Jan 2021 5.000 call in.finance.yahoo.com - January 16 at 2:48 AM
	CEMI Jan 2021 12.500 put in.finance.yahoo.com - January 16 at 2:48 AM
	Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems finance.yahoo.com - January 14 at 5:45 PM
	Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors finance.yahoo.com - December 17 at 7:34 PM
	Roche CEO Says Testing Demand Could Outstrip Supply for Months baystreet.ca - December 17 at 9:33 AM
	Is Chembio Diagnostics (NASDAQ:CEMI) Using Too Much Debt? finance.yahoo.com - December 5 at 6:24 PM
	Stock Alert: Chembio Diagnostics Declines Following FDA Response nasdaq.com - December 4 at 4:36 PM
	Chembio Diagnostics (CEMI) Surges: Stock Moves 8.5% Higher finance.yahoo.com - December 3 at 9:25 AM

Date	Company	Brokerage	Action
4/1/2021	Actinium Pharmaceuticals	HC Wainwright	Lower Price Target
12/31/2020	Actinium Pharmaceuticals	William Blair	Reiterated Rating
11/5/2020	Actinium Pharmaceuticals	Alliance Global Partners	Initiated Coverage
8/21/2020	Actinium Pharmaceuticals	Maxim Group	Reiterated Rating
2/26/2019	Actinium Pharmaceuticals	Oppenheimer	Set Price Target
12/4/2018	Actinium Pharmaceuticals	Roth Capital	Set Price Target
8/15/2018	Actinium Pharmaceuticals	B. Riley	Set Price Target
4/5/2021	Mereo BioPharma Group	Needham & Company LLC	Initiated Coverage
10/10/2019	Mereo BioPharma Group	SVB Leerink	Reiterated Rating
11/18/2020	Cocrystal Pharma	Noble Financial	Reiterated Rating
7/17/2018	Cocrystal Pharma	EuroPacific Canada	Initiated Coverage
3/18/2021	PhaseBio Pharmaceuticals	Stifel Nicolaus	Reiterated Rating
8/25/2020	PhaseBio Pharmaceuticals	Citigroup	Lower Price Target
9/24/2019	PhaseBio Pharmaceuticals	Cowen	Reiterated Rating
3/11/2021	Chembio Diagnostics	Colliers Securities	Reiterated Rating
12/3/2020	Chembio Diagnostics	Craig Hallum	Upgrade
6/17/2020	Chembio Diagnostics	Robert W. Baird	Downgrade
6/17/2020	Chembio Diagnostics	Benchmark	Downgrade
6/17/2020	Chembio Diagnostics	Canaccord Genuity	Downgrade
12/19/2018	Chembio Diagnostics	Dougherty & Co	Initiated Coverage

(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources